SIK2
| Official symbol: | SIK2 |
| Full name: | salt inducible kinase 2 |
| Location: | 11q23.1 |
| Also known as: | SNF1LK2, DKFZp434K1115, KIAA0781, QIK, LOH11CR1I |
| Entrez ID: | 23235 |
| Ensembl ID: | ENSG00000170145 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 1.08 (Driver) |
|
|
|
| Recurrently deleted in 6 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 5 |
|
|
| Fusions detected in 5 cancer type(s) |
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 36.53 (Percentile rank: 57.34%) |
| PubTator score: | 17.80 (Percentile rank: 50.04%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | |
